Use of Impella RP Flex in Post-Heart Transplant Patients with RV Primary Graft Dysfunction

TL;DR

This study evaluates the use of the Impella RP Flex device to treat right ventricular dysfunction after heart transplants, finding it effective but noting significant bleeding and kidney issues.

Contribution

The study provides clinical evidence on the safety and effectiveness of the Impella RP Flex for treating RV-PGD post-heart transplant.

Findings

Five patients with RV-PGD showed recovery of right ventricular function after an average of 8.6 days of Impella RP Flex support.

Common complications included hemolysis, bleeding, and acute kidney dysfunction requiring hemodialysis.

No tricuspid valve injuries were observed, and one device showed transient biologic material ingestion during weaning.

Abstract

Background: Right ventricular primary graft dysfunction (RV-PGD) is a rare but serious complication following heart transplantation, associated with a high morbidity and mortality. Temporary mechanical circulatory support is indicated when patients fail to respond to pharmacological therapy. This study aimed to evaluate the outcomes of patients with RV-PGD who received RV mechanical support with the Impella RP Flex device at our institution. Methods: Medical records of patients with RV-PGD supported by the Impella RP Flex device between December 2022 and March 2024 were reviewed retrospectively to assess survival, procedural complications, duration of support, and end organ dysfunction. Results: Of the 20 patients reviewed, 5 met the inclusion criteria. All five patients demonstrated recovery of RV function after a mean support duration of 8.6 ± 3.05 days. One pump showed transient evidence of biologic material ingestion during a weaning trial. No cases of tricuspid valve injury were observed. The most common complications were hemolysis, bleeding, and acute kidney dysfunction, with all patients requiring hemodialysis. Conclusions: Impella RP Flex support is safe and effective for managing primary and isolated RV-PGD without the need for additional blood oxygenation. However, bleeding complications requiring intervention remain a significant concern, and further evaluation of renal recovery is warranted.